Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16768108 | 1.00 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2SLC6A3MEN1 | |
| SCHEMBL16768109 | 1.00 | HCAR2 (0.40) | HCAR2KEAP1NFE2L2SLC6A3MEN1 | |
| SCHEMBL14861968 | 0.95 | HCAR2 (0.41) | HCAR2KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL14861966 | 0.95 | HCAR2 (0.41) | HCAR2KEAP1NFE2L2MEN1KMT2A | |
| SCHEMBL18269615 | 0.82 | L3MBTL1 (0.46) | HCAR2MGLL | |
| SCHEMBL18269654 | 0.82 | L3MBTL1 (0.46) | HCAR2MGLL | |
| SCHEMBL31536564 | 0.80 | PTPN2 (0.31) | — | |
| SCHEMBL25766428 | 0.80 | PTPN2 (0.31) | — | |
| SCHEMBL9218046 | 0.79 | KMT2A (0.32) | KMT2A | |
| SCHEMBL18269628 | 0.78 | HTT (0.36) | MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6610711-B2 | 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-08-26 | — | — | US | disclosed |
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | PFIZER INC. | 2003-04-24 | — | — | US | disclosed |
| EP-0482771-B1 | Heterocyclic acids | ZENECA LTD (GB) | 1997-06-18 | — | — | EP | disclosed |
| US-5410064-A | Thromboxane A2 antagonists and inhibitors of thromboxane A2 synthase | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1995-04-25 | — | — | US | disclosed |
| US-5219874-A | Heterocyclic acids | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-06-15 | — | — | US | disclosed |
| EP-0482771-A2 | Heterocyclic acids | ZENECA LIMITED (GB) | 1992-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078282-A1 | Novel 4-phenylpiperidines for the treatment of pruritic dermatoses | HRH2, HRH4, HRH1 | HCAR2 256/4885KEAP1 594/4885NFE2L2 1114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.